KAT5 / Tip60 - the acetyltransferase in the only direct KMT2A-fusion histone-variant result, and both fusions tested were myeloid
also called Tip60 · HTATIP · TIP60 · HIV-1 Tat interactive protein · 60 kDa Tat-interactive protein
Tip60 is an enzyme that hangs an acetyl tag on a swapped-in version of a histone protein, and two KMT2A fusion proteins drag it to the exact genes that drive the leukaemia. Deleting Tip60 in mice stops those two leukaemias from ever forming - a striking result, but both leukaemias tested were myeloid, and the fusion that causes most infant ALL was not among them.
The same thing, for a scientist
Tip60 (KAT5, Q92993, 513 aa) is the catalytic subunit of the NuA4/TIP60 complex, a MYST-family acetyltransferase. In the single most fusion-directed acetylation result this graph holds, Yamagata et al. showed Tip60 is **recruited by MLL-AF10 and MLL-ENL to the Hoxa9 locus**, where it **acetylates the histone variant H2A.Z**, promoting Hoxa9 expression; Tip60 was required for HoxA-cluster and Meis1 expression, and **conditional deletion of Tip60 prevented the development of both MLL-AF10 and MLL-ENL leukaemia** [E1]. That is a cleaner fusion-directed statement than anything in the KAT8/MOF literature, because the mechanism runs THROUGH the HOXA programme rather than around it - the exact test `mechanism-kat8-mof-requirement-is-myeloid-not-fusion-specific` applies, and MOF fails it precisely because MOF loss leaves Hoxa9 running. **But it does not make Tip60 fusion-specific, and this entry does not claim it is.** Both fusions tested are myeloid (the paper's own title says acute myeloid leukemia); **the index fusion of this graph, KMT2A::AFF1, was not tested**, nor was any lymphoid model, nor was a lineage-matched non-fusion myeloid leukaemia - so the discriminating comparator is again absent. Outside that paper KAT5 has almost no KMT2A literature: the alias-inclusive title/abstract query returns **7 records**, of which exactly one is a KMT2A-fusion functional study [E2]. This entry closes a forward reference opened by `gene-ep400` in the histone-chaperone beat; EP400 is the H2A.Z-exchange ATPase of the same NuA4/TIP60 complex, which is why the two belong together.
Why this is the strongest fusion-directed acetylation result in the graph
Set the Tip60 result beside the acetylation findings this graph already holds, on the test mechanism-kat8-mof-requirement-is-myeloid-not-fusion-specific sets out:
| enzyme | fusion recruits it? | acts on the HOXA programme? | conditional deletion blocks leukaemia? | lineage-matched non-fusion comparator |
|---|---|---|---|---|
| KAT5 / Tip60 | yes - MLL-AF10 and MLL-ENL, at Hoxa9 1 | yes - required for HoxA and Meis1 expression 1 | yes, both fusions 1 | absent |
| KAT8 / MOF | binds MLL1; not shown for a fusion | no - MOF loss does not clearly downregulate Hoxa9 | yes (MLL-AF9, NUP98-HOXA9) | absent |
The third column is the one that matters. MOF's requirement was shown to run through DNA damage and global H4K16ac while leaving the HOXA cluster running, which is what made it a lineage requirement rather than a fusion one. Tip60's requirement runs through Hoxa9 and Meis1, at a locus the fusion itself brings it to. That is the shape of a fusion-directed dependency.
What is still missing is the fourth column, and it is missing for every acetyltransferase in this graph. Nobody has deleted Kat5 in a lineage-matched myeloid leukaemia driven by neither fusion. Until someone does, the honest verdict is: mechanistically fusion-directed, specificity untested.
The mark is on a histone variant, not on bulk chromatin
The substrate reported is H2A.Z, a replication-independent histone H2A variant, not bulk H2A 1. That matters twice.
First, it ties this entry to the histone-chaperone layer rather than the bulk-acetylation layer. H2A.Z is deposited by the SRCAP and NuA4/TIP60 complexes; EP400 is the ATPase that performs H2A.Z exchange within NuA4/TIP60, and gene-ep400 already exists carrying the forward reference this entry closes. Writer and exchanger sit in one complex, and the fusion recruits the complex.
Second, it narrows what an eraser would have to do. Bulk histone deacetylation by a pan-HDAC inhibitor is a different physical event from removing an acetyl group from a variant nucleosome at one locus, and no paper found in this beat measures H2A.Z acetylation under any HDAC inhibitor. The writer half of this particular cycle is measured; the eraser half is not. That asymmetry is what mechanism-acetylation-is-a-cycle-not-a-mark exists to record.
What was tested, and what a reader will assume was tested
Stated plainly, because the paraphrase drifts:
- Tested: MLL-AF10, MLL-ENL. Mouse. Myeloid.
- Not tested: KMT2A::AFF1, the index fusion of this graph and the commonest fusion in infant ALL. KMT2A::MLLT3. Any lymphoid model. Any non-fusion leukaemia comparator.
- Not available: a selective KAT5 inhibitor. None is in clinical development and none was used in the paper.
A sentence like "Tip60 is required for KMT2A-fusion leukaemia" generalises from two myeloid fusions to a family that is predominantly lymphoid in infants. This graph's standing finding - that the differentiation narrative is an AML story infant ALL entries should not inherit - applies here without modification.
Bounded absence: the KAT5 literature in this disease
Searched 2026-09-20, title/abstract, aliases included because KAT5 publishes under three names:
(MLL[tiab] OR KMT2A[tiab]) AND (KAT5[tiab] OR Tip60[tiab] OR HTATIP[tiab]) -> 7 records
Title-checked, the seven are: PMID 33967269 (this entry's 1); 23994619 (symplekin restraining MOZ and MLL on HOXA9); 22094252 (CBX8 in MLL-AF9, already in this graph); 22199269 (breast-cancer histone-modifier expression profiling); 20188723 (a C. elegans MLL-like complex); 20018852 (a MOF-containing HAT complex distinct from MSL); 16510874 (APC, beta-catenin and H3K4 at Wnt targets). Exactly one is a KMT2A-fusion functional study of KAT5 2.
So the strongest fusion-directed acetyltransferase result in this graph rests on a single paper from a single laboratory, unreplicated, five years old. That is the correct confidence anchor for everything above.
| uniprot | Q92993 |
|---|---|
| length AA | 513 |
| gene symbol | KAT5 |
| accession resolution | gene_exact:KAT5 AND organism_id:9606 AND reviewed:true returned exactly 1 reviewed row; primary gene name read back as KAT5 (rule 62 applied). No paralogue collision found for this symbol. |
| family | MYST-family lysine acetyltransferase; catalytic subunit of the NuA4/TIP60 complex |
| complex | NuA4/TIP60, with EP400 as the H2A.Z-exchange ATPase (see gene-ep400) |
| substrate in this disease | H2A.Z (histone variant), at the Hoxa9 locus |
| lineage of tested models | myeloid (AML) |
| lineage matched non fusion comparator | false |
| recruited by fusion | true |
| acts through hoxa programme | true |
| conditional deletion prevents leukaemia | yes, for MLL-AF10 and MLL-ENL |
| selective inhibitor in clinic | false |
| symbol literature count mll kmt2a | 7 |
| fusion functional studies among them | 1 |
| closes forward reference from | gene-ep400 |
| subnuclear localization | chromatin-associated at fusion-target loci (a genomic address by ChIP) plus reported condensate behaviour; NO nuclear-body, speckle, nucleolar or heterochromatin assignment exists for KAT5 in any source read for this beat. |
| shown for fusion | PARTIAL, and the partner is the wrong one. Tip60/KAT5 recruitment to chromatin IS demonstrated in an MLL-fusion context - but in murine MLL-AF10 and MLL-ENL myeloid leukaemia, not in KMT2A::AFF1 and not in human infant B-lineage disease (brief rule 73). (Tip60 OR KAT5)[tiab] AND (KMT2A OR MLL)[tiab] returns 7 records (2026-09-21) and PMID 33967269 is the only one carrying a fusion-context chromatin measurement. No microscopy, fractionation or subnuclear assignment of KAT5 has been done in any KMT2A-rearranged cell. |
| identifier trap | KAT5 (Q92993, 513 aa), KAT7 (O95251, 611 aa) and KAT8 (Q9H7Z6, 458 aa) are three different proteins, all present in this graph, whose recommended protein names differ only in a trailing digit ('Histone acetyltransferase KAT5/KAT7/KAT8'). Lengths are 55-153 aa apart so verify-accessions.py CAN catch a swap here, unlike the RAS, IMPDH1/2, BMI1/CDK6 and H2AZ1/2 cases - but reading the protein name back cannot. Verified live against UniProt REST 2026-09-21. |
fusions tested
[ "MLL-AF10", "MLL-ENL" ]
fusions not tested
[ "KMT2A::AFF1 (the index fusion)", "KMT2A::MLLT3", "any lymphoid model" ]
essentiality
{
"depmap_common_essential": null,
"note": "DepMap was not queried for KAT5 in this beat. Before any target claim is made, the KMT2A-rearranged versus other-leukaemia split and the pan-essentiality bar in ana-the-acetyltransferase-signal-is-paralogue-specific-and-does-not-survive-pan-essentiality must both be applied."
}localization
{
"subcellular": "Predominantly nuclear and chromatin-associated, but NOT exclusively: in breast and lung cancer cells a cytoplasm-restricted Tip60 retains tumour-suppressor activity, so a nuclear-only description of KAT5 is wrong. UniProt Q92993 (KAT5_HUMAN, Histone acetyltransferase KAT5, 513 aa) was read back only to confirm the identifier; its localisation annotation was not used.",
"subnuclear": "chromatin at defined loci, and damage-induced foci - but NO named nuclear body. In MLL-AF10 and MLL-ENL leukaemia Tip60 is recruited to the Hoxa9 locus by the fusion, where it acetylates H2A.Z; that is a GENOMIC address in the right disease family, not a spatial compartment. A phase-separation property has been reported for TIP60 and is disrupted by the cancer-associated G400 mutation; that is a condensate claim and is graded against this graph's condensate-evidence standard.",
"how_shown": "chromatin immunoprecipitation at Hoxa9 plus conditional Tip60 deletion in MLL-AF10 and MLL-ENL leukaemia (PMID 33967269); localisation-restricted constructs with a functional readout (PMID 33155839); in-cell droplet imaging with a point mutant (PMID 39965267)",
"systems": "murine MLL-AF10 and MLL-ENL myeloid leukaemia for the chromatin work; human breast and lung cancer lines for the cytoplasmic pool",
"node": "localization-chromatin-bound-versus-soluble-fraction-kmt2a"
}localization counted absence
{
"query": "(Tip60[tiab] OR KAT5[tiab]) AND (KMT2A[tiab] OR MLL[tiab])",
"records": 7,
"operand_controls": {
"(Tip60 OR KAT5 OR HTATIP)[tiab] AND (\"nuclear bodies\" OR nucleolus OR nucleolar OR speckle* OR cytoplasm* OR subnuclear)[tiab]": 57
},
"date": "2026-09-21",
"tool": "PubMed E-utilities esearch",
"bound": "zero SUBNUCLEAR observations in titles and abstracts; supporting figures not searched"
}depmap kmt2a selectivity
{
"chronos_mean_kmt2a_rearranged": -0.6615,
"chronos_mean_other_leukaemia": -0.7024,
"difference": 0.0409,
"pan_essentiality_all_lines": -0.6048,
"selectivity_rank": 13972,
"rank_denominator": 17728,
"provenance": "Joined 2026-09-21 from analyses/depmap-kmt2a-selective-scan-full (generated 2026-09-19T10:12:06Z), the project's own genome-wide scan over 11 KMT2A-rearranged and 43 other leukaemia DepMap lines. NOT re-fetched and NOT independent of that scan: every caveat it carries applies here, including that the KMT2A-rearranged arm is a small number of lines drawn from nine individuals, that the rank denominator is 17,728 genes, and that a difference is not a dependency. Added because only 26 of 308 gene entries carried this number, which made any KMT2A-selectivity question answerable for 8% of the corpus.",
"how_to_read": "A negative difference means MORE required in KMT2A-rearranged lines than in other leukaemia lines. A rank near 17,728 is ANTI-selective. Neither is evidence of a fusion-driven dependency on its own: check pan_essentiality_all_lines before calling anything selective, and note that a paralogue-redundant gene can score near zero for reasons that have nothing to do with this disease - see ana-the-paralogue-redundancy-excuse-is-not-tested-and-my-proxy-decided-the-answer."
}cell type
{
"evidence_class_key": "concept-expressed-required-maintains-three-evidence-classes",
"identifier_note": "KAT5 is TIP60. KAT5, KAT7 (HBO1) and KAT8 (MOF) are three different proteins and this graph contains all three; a claim about one must not be transferred to another. KAT5 is Q92993, 513 aa.",
"expressed_in": {
"class": 1,
"summary": "ubiquitous; KAT5/Tip60 is the catalytic subunit of the NuA4/TIP60 complex and is not cell-type restricted."
},
"required_in": {
"class": 2,
"claim": "In MICE, conditional knockout of Kat5/Tip60 shows a critical requirement for HAEMATOPOIETIC STEM CELL MAINTENANCE at BOTH the embryonic and the adult stage, and the requirement depends on its acetyltransferase activity; Tip60 colocalises with c-Myc in murine HSPCs, Tip60 deletion suppresses Myc target gene expression, and acetylated H2A.Z is enriched at Tip60-bound active chromatin with the acH2A.Z/H2A.Z ratio falling robustly on deletion [E_q69_ct1].",
"pmids": [
"32542325"
],
"system_named_in_the_claim": "murine normal haematopoiesis, conditional knockout - not leukaemia, not human, not KMT2A-rearranged",
"the_developmental_stage_is_part_of_the_answer": "the requirement holds in BOTH embryonic and adult HSCs. That distinguishes KAT5 from its cousin KAT8/MOF, whose HAT activity is required for adult but NOT early fetal haematopoiesis - a difference recorded on gene-kat8 in this graph. Two members of the same acetyltransferase family, opposite answers on the fetal compartment, which is the compartment this disease starts in."
},
"not_required_in": {
"claim": "NO KMT2A-selective requirement. Chronos -0.6615 in the KMT2A-rearranged arm against -0.7024 in other leukaemias, difference +0.0409, rank 13,972 of 17,728 - the ANTI-SELECTIVE half. Pan-essentiality -0.6048, so this is a broadly required gene with no dynamic range problem and no fusion preference.",
"rescoping_this_forces": "the entry's fusion-recruitment material (Tip60 recruitment in murine MLL-AF10 and MLL-ENL) should be read as 'KAT5 is used by these fusions', which is what the papers show, and NOT as 'KAT5 is a fusion-selective vulnerability', which the screen contradicts. Unselective is not unimportant - -0.60 is a real requirement - but it is not a selectivity."
},
"nodes": [
"cell-type-hsc-bone-marrow",
"cell-type-fetal-liver-hsc"
],
"context": "murine normal haematopoiesis for the requirement; murine MLL-AF10/MLL-ENL myeloid leukaemia for the fusion-recruitment material already in this entry"
}cell state
{
"evidence_class_key": "concept-expressed-required-maintains-three-evidence-classes",
"maintains_state": {
"class": 3,
"states": [
"cell-state-stem-like-self-renewal"
],
"claim": "In MICE, Tip60 maintains the haematopoietic stem cell state through H2A.Z acetylation at active chromatin and activation of MYC target genes associated with HSC maintenance, cell cycling and DNA repair; the two defining HSC properties the paper names are SELF-RENEWAL and DIFFERENTIATION [E_q69_ct1].",
"pmids": [
"32542325"
],
"system_named_in_the_claim": "murine haematopoietic stem and progenitor cells in normal haematopoiesis"
},
"bounded_query": {
"date": "2026-09-21",
"tool": "NCBI esearch db=pubmed",
"query": "(KAT5 OR Tip60)[tiab] AND (\"hematopoietic stem\" OR \"haematopoietic stem\")[tiab]",
"count": 16,
"on_topic_after_title_check": 1,
"note": "the single squarely on-topic record is the conditional knockout. A narrower shape, Tip60[tiab] AND (hematopoietic OR haematopoietic)[tiab] AND (maintenance OR self-renewal OR quiescence)[tiab], returns 7 and recovers the same paper.",
"alias_precision": "Tip60 is a clean token - unlike MOF for KAT8, which returns 28,480 mostly metal-organic-framework records. The KAT5 literature does not have that problem and the counts here are usable as counts.",
"bound": "titles and abstracts only; supporting figures not searched (brief rule 80)"
},
"confidence": "strong",
"caveats": "Murine conditional knockout in normal haematopoiesis. No human HSC, no KMT2A-rearranged cell, no infant B-lineage measurement. 'HSC maintenance' is a transplant and immunophenotype claim in mouse. The MYC-target mechanism is correlative at the level of the abstract - colocalisation plus expression loss - and the abstract does not report a MYC epistasis experiment. And the DepMap arm places KAT5 in the anti-selective half, so nothing here supports a fusion-selective reading.",
"counter_evidence": {
"note": "A TIP60 requirement is not specific to this disease's fusion. ZMYND11-MBTD1, an entirely different leukaemogenic fusion with no KMT2A involvement, induces leukaemia by HIJACKING the NuA4/TIP60 acetyltransferase complex through a PWWP-mediated chromatin association mechanism. So NuA4/TIP60 is a general route into leukaemic transcription that several unrelated fusions take, which is consistent with the anti-selective DepMap placement and argues against a KMT2A-specific TIP60 strategy.",
"citation": {
"title": "ZMYND11-MBTD1 induces leukemogenesis through hijacking NuA4/TIP60 acetyltransferase complex and a PWWP-mediated chromatin association mechanism.",
"year": 2021,
"venue": "Nat Commun",
"pmid": "33594072",
"type": "paper"
}
}
}- KAT5/Tip60 is a core DNA-damage-response and cell-cycle acetyltransferase in every dividing cell. An inhibitor would be a broad genotoxic-response agent before it was a leukaemia drug, and the patients are infants whose normal haematopoiesis and neurodevelopment are running at full rate.
- The deletion experiment tests leukaemogenesis - whether Tip60 is needed to MAKE the leukaemia. Established leukaemia in a child is a maintenance problem, and this graph has already recorded a case (KAT8/MOF) where the transformation and maintenance answers differ.
- No selective KAT5 inhibitor exists, so any near-term attempt to exploit this would use a pan-MYST or NuA4-complex-level tool. That is the same failure that makes every CK2 result CK2-level rather than subunit-level, and it would arrive with the same false precision.
- If Tip60's requirement is myeloid rather than fusion-directed - which nobody has tested - a trial in KMT2A-rearranged AML would be positive for the wrong reason and would not transfer to the infant ALL population this graph exists to serve.
- a cytoplasmic pool a nuclear rationale ignores - Conditional Tip60 deletion prevents MLL-AF10 and MLL-ENL leukaemia, which makes KAT5 a candidate target - but a cytoplasm-restricted Tip60 retains tumour-suppressor activity, so systemic KAT5 inhibition removes a function the leukaemia rationale does not account for.
- KAT5/Tip60 is required for haematopoietic stem cell maintenance in BOTH embryonic and adult mice, and the requirement depends on its acetyltransferase activity (PMID 32542325). An enzymatic TIP60 inhibitor is therefore predicted to hit the normal HSC compartment through the same activity it is meant to hit the leukaemia with - essential-function toxicity in the exact tissue being treated, in a patient population of infants whose marrow has to last eighty years.
- The selectivity argument is not available. This project's own genome-wide scan puts KAT5 at rank 13,972 of 17,728, i.e. LESS required in KMT2A-rearranged lines than in other leukaemias (difference +0.0409), with pan-essentiality -0.6048 and no floor compression to excuse it. And an unrelated fusion, ZMYND11-MBTD1, reaches leukaemia through the same NuA4/TIP60 complex (PMID 33594072). Whatever therapeutic case exists for TIP60 here, it is not a fusion-selectivity case.
- Does conditional Kat5 deletion block a KMT2A::AFF1 lymphoid leukaemia? The index fusion of this graph has never been tested against the strongest fusion-directed acetyltransferase result in it.
- Does a lineage-matched non-fusion myeloid leukaemia tolerate Kat5 loss? Without that arm the Tip60 result is exactly where the MOF result was before the comparator killed it.
- Is H2A.Z acetylation at fusion target loci reversed by any HDAC inhibitor used in this disease? No paper found in this beat measures it, so the eraser half of this specific cycle is unwritten.
- Do EP400-mediated H2A.Z exchange and Tip60-mediated H2A.Z acetylation act as one step or two at the Hoxa9 locus, and can they be separated pharmacologically?
- Has anyone replicated the Yamagata result? As of 2026-09-20 the symbol literature contains no second KMT2A-fusion KAT5 study.
- Does Tip60 occupy the HOXA cluster in a human KMT2A::AFF1 B-lineage cell, as it does at Hoxa9 in murine MLL-AF10 and MLL-ENL myeloid leukaemia - and is the H2A.Z acetylation step the same one? Every existing datum is murine and myeloid.
- E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.paper
Tip60 is required for HoxA cluster and Meis1 expression and for the development of MLL-fusion leukaemia; Tip60 is recruited by MLL-AF10 and MLL-ENL fusions to the Hoxa9 locus where it acetylates H2A.Z, thereby promoting Hoxa9 gene expression; and conditional deletion of Tip60 prevented the development of MLL-AF10 and MLL-ENL leukaemia.
Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia. · Yamagata K, Shino M, Aikawa Y, Fujita S, Kitabayashi I · Leukemia 35(10):2840-2853 2021What this evidence cannot show
Confidence is 'established' for the result WITHIN its reported system and no further: two myeloid mouse fusion models, MLL-AF10 and MLL-ENL. The index fusion KMT2A::AFF1 was not tested, no lymphoid model was tested, and no lineage-matched non-fusion myeloid leukaemia arm was run - so the experiment cannot distinguish a fusion-directed requirement from a myeloid one, which is precisely the failure mode mechanism-kat8-mof-requirement-is-myeloid-not-fusion-specific was written to catch. Single laboratory, unreplicated as of this search. Only the abstract was read; the paper is in Leukemia (Springer Nature), efetch reports no PMC id, and full text was not retrieved in this beat.
Evidence that argues against this (1)
- This graph's own standing finding is that an acetyltransferase requirement in a KMT2A-fusion model has already turned out to be lineage-wide rather than fusion-specific once a lineage-matched comparator was applied: KAT8/MOF's Cohen's d between KMT2A-rearranged and other leukaemia lines was 0.003, smaller than a pan-essential control's, while the published mouse experiment looked just as decisive as this one. No such comparison has been run for KAT5, so the Tip60 result currently sits exactly where the MOF result sat before it was tested. Valerio DG et al. 2017
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.database
A title/abstract search for KAT5 and its aliases against MLL or KMT2A returns 7 records, of which exactly one is a KMT2A-fusion functional study of KAT5.
PubMed E-utilities esearch: (MLL[tiab] OR KMT2A[tiab]) AND (KAT5[tiab] OR Tip60[tiab] OR HTATIP[tiab]), run 2026-09-20, count 7, all seven title-checked by efetch · NCBI E-utilities · PubMed 2026What this evidence cannot show
A title/abstract symbol search cannot reach a paper that frames its work at the level of the NuA4/TIP60 complex without naming the catalytic subunit, and this project has logged that exact miss for the NSL complex and for Mediator. A complex-name phrase search was not run for NuA4 in this beat, so this count bounds the SYMBOL literature and not the complex literature. The query translation was read and contained no [UID] rewrite.
Evidence that argues against this (1)
- This project has twice found a counted absence built from gene symbols missed most of the relevant literature - SEPTIN9 returned 1 record where SEP9 returned 20, and the paper establishing that NUP98 fusions bind the NSL complex is unreachable from any KANSL subunit symbol. A low symbol count is an upper bound on confidence, not a measurement of how much work exists. Michmerhuizen NL et al. 2025
- E3established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.database
Human KAT5 is UniProt Q92993, primary gene name KAT5, 513 amino acids, with TIP60 and HTATIP as gene synonyms and 'Histone acetyltransferase KAT5' as its primary protein name.
UniProtKB Q92993 (KAT5_HUMAN), Histone acetyltransferase KAT5 · UniProt Consortium · UniProtKB, retrieved 2026-09-20 2026What this evidence cannot show
Resolved per rule 62: gene_exact:KAT5 AND organism_id:9606 AND reviewed:true was run with gene_primary requested, returned exactly one reviewed row, and that row's PRIMARY name was read back as KAT5 before the accession was stored. 513 aa is the canonical isoform; KAT5 has several isoforms and a residue number taken from a paper using a different one will not match this numbering.
Evidence that argues against this (1)
- A reviewed database record fixes the canonical sequence on the date it was read and nothing more. It does not establish which isoform is expressed in KMT2A-rearranged blasts, and this beat's own findings turn on distinctions a canonical record hides - HDAC9's catalytically inactive MITR form, and the nomenclature collision in which HDAC9's protein name reads 'Histone deacetylase 7B'. Accession and length are asserted here so a swap fails the validator, not because they carry biological weight. Vega-Garcia N et al. 2018
- E_q65_loc1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In murine MLL-AF10 and MLL-ENL acute myeloid leukaemia, Tip60 is recruited by the fusion to the Hoxa9 locus where it acetylates H2A.Z to promote Hoxa9 expression, and conditional Tip60 deletion prevents leukaemia development - placing KAT5 on chromatin at fusion target genes in an MLL-fusion context.
Tip60 activates Hoxa9 and Meis1 expression through acetylation of H2A.Z, promoting MLL-AF10 and MLL-ENL acute myeloid leukemia. · Yamagata K, et al. · Leukemia 2021;35:2840-2853 2021What this evidence cannot show
Murine, myeloid, and MLL-AF10/MLL-ENL - not KMT2A::AFF1 and not infant B-lineage (brief rule 73). ChIP gives a genomic address, not a spatial compartment. Abstract only.
Evidence that argues against this (1)
- KAT5 is not obligately nuclear: a Tip60 construct restricted to the cytoplasm retains tumour-suppressor activity in breast and lung cancer cells, so writing KAT5 as a chromatin protein full stop mispredicts what happens when its nuclear pool is removed. Ravichandran P et al. 2020
- E_q65_loc2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
Nuclear localisation is not required for Tip60's tumour-suppressor activity in breast and lung cancer cells, which establishes a functional cytoplasmic pool of KAT5.
Nuclear Localization Is Not Required for Tip60 Tumor Suppressor Activity in Breast and Lung Cancer Cells. · Ravichandran P, et al. · DNA Cell Biol 2020;39:2077-2084 2020What this evidence cannot show
Solid-tumour lines; the readout is tumour-suppressor activity rather than a quantitative partition, and forced-localisation constructs over-express. Abstract only.
Evidence that argues against this (1)
- The fusion-relevant activity of Tip60 in this disease is chromatin acetylation at Hoxa9, which a cytoplasmic pool cannot perform; these are different functions of one protein rather than a contradiction. Yamagata K et al. 2021
- E_q65_loc3weak confidence 2 of 5: Preliminary, small, indirect, or not yet peer reviewed.paper
TIP60 has been reported to phase-separate, and the cancer-associated glycine-400 mutation disrupts both that phase-separation property and catalytic activity, compromising DNA damage repair.
Cancer-associated mutation at glycine 400 in TIP60 disrupt its phase separation property and catalytic activity resulting in compromised DNA damage repair function of the cell. · Gupta H, Singh A, Gupta A · Biochem Biophys Res Commun 2025;753:151457 2025What this evidence cannot show
Graded weak deliberately. This graph's condensate standard holds that 1,6-hexanediol sensitivity and classical FRAP cannot distinguish liquid-liquid phase separation from binding to spatially clustered sites, and that punctate appearance in an over-expression system is weak evidence about the endogenous protein. The rival model - Tip60 clustering on chromatin at fusion target loci - is directly supported by the ChIP evidence above. Abstract only.
Evidence that argues against this (1)
- The rival model is not a nullity: clustered binding predicts sequence-specific targeting where phase separation predicts bulk enrichment, and the MLL-fusion data show exactly sequence-specific targeting to Hoxa9. Yamagata K et al. 2021
- E_q69_ct1strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In MICE, conditional gene-knockout models demonstrate a critical requirement of lysine acetyltransferase 5 (Kat5, Tip60) for haematopoietic stem cell maintenance at both the embryonic and the adult stage, dependent on its acetyltransferase activity; genome-wide chromatin and transcriptome profiling in murine haematopoietic stem and progenitor cells shows Tip60 colocalising with c-Myc, Tip60 deletion suppressing Myc target gene expression associated with HSC maintenance, cell cycling and DNA repair, and acetylated H2A.Z enriched at Tip60-bound active chromatin with a robust reduction in the acH2A.Z/H2A.Z ratio on deletion.
Lysine acetyltransferase Tip60 is required for hematopoietic stem cell maintenance. · Numata A, Kwok HS, Zhou QL, Li J, Tirado-Magallanes R, Angarica VE, Hannah R, Park J, Wang CQ, Krishnan V, Rajagopalan D, Zhang Y, Zhou S, Welner RS, Osato M, Jha S, Bohlander SK, Göttgens B, Yang H, Benoukraf T, Lough JW, Bararia D, Tenen DG · Blood 2020What this evidence cannot show
Abstract read in full; full text not read. Murine normal haematopoiesis, conditional knockout - not leukaemia, not human, not KMT2A-rearranged (brief rule 73). The MYC-target link is colocalisation plus expression change at abstract level, with no epistasis experiment reported there. 'HSC maintenance' is a transplant and immunophenotype claim.
Evidence that argues against this (1)
- TIP60 is not a KMT2A-specific route into leukaemia: ZMYND11-MBTD1, a fusion with no KMT2A component, induces leukaemogenesis by hijacking the same NuA4/TIP60 complex. Combined with this project's DepMap placement of KAT5 in the anti-selective half (rank 13,972 of 17,728), the case for a fusion-selective TIP60 dependency is weak. Nat Commun 2021
MLL-AF10 recruits Tip60 to the Hoxa9 locus
MLL-ENL recruits Tip60 to the Hoxa9 locus
Tip60 acetylates H2A.Z at Hoxa9, activating its expression
Tip60 required for Meis1 expression in MLL-fusion leukaemia
both are subunits of the NuA4/TIP60 complex; EP400 is its H2A.Z-exchange ATPase
conditional Tip60 deletion prevents MLL-AF10 and MLL-ENL AML
both MYST acetyltransferases required in KMT2A-fusion models; KAT8 failed the lineage-matched test, KAT5 has not been given it
the convergence test this entry applies to Tip60; the comparator arm is absent for both
Tip60 supplies the writer half of the histone cycle at a fusion target locus; the eraser half was never measured
- analogous to →KAT7 / HBO1 — an enzyme, a leukaemia-stem-cell dependency, and an inhibitor already in a crystal
both MYST-adjacent acetyltransferases nominated in fusion leukaemia; KAT7 has a dossier and failed the pan-essentiality bar
Tip60 acetylates H2A.Z at the Hoxa9 locus when recruited by MLL-AF10 or MLL-ENL
hijacks NuA4/TIP60 through the retained MBTD1 MBT repeats; the Tip60 interaction is required for transformation of murine HSPCs (MOUSE)
stable subunit of the same NuA4/TIP60 complex; MBTD1's H4K20me reading is what lets TIP60 reach specific promoters
the catalytic subunit delivered in place of DOT1L
non-catalytic subunit of the NuA4/TIP60 acetyltransferase complex whose catalytic subunit is KAT5
the catalytic subunit of the NuA4/TIP60 complex every 5' half of this family belongs to
Tip60/KAT5 is chromatin-bound at Hoxa9 in MLL-AF10 and MLL-ENL leukaemia by ChIP; the soluble and cytoplasmic pools are measured only in solid-tumour lines
the TIP60 G400 phase-separation report is graded against this graph's condensate standard, which is why KAT5's condensate claim is weak rather than moderate
conditional Kat5/Tip60 knockout shows a critical, HAT-activity-dependent requirement for adult haematopoietic stem cell maintenance (murine; PMID 32542325)
the same conditional knockout shows the requirement at the EMBRYONIC stage too - unlike KAT8/MOF, whose HAT activity is dispensable in early fetal haematopoiesis (murine; PMID 32542325)
- regulates →The stem-like self-renewal state — a limited stem-cell module grafted onto a committed cell
Tip60 maintains the HSC state through H2A.Z acetylation and MYC target activation; self-renewal and differentiation are the two properties the paper names (murine; PMID 32542325)
cell-type contrast inside one acetyltransferase family: KAT5 is required in BOTH fetal and adult HSCs while KAT8/MOF HAT activity is required in adult but not early fetal haematopoiesis. The fetal compartment is where this disease starts.